DOCSLIB.ORG

Supplementary Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

aabb d ccd a b c d ab a b c d Supplementary Figure S1: Gene ontology analysis of genes upregulated in pancreatic CAFs relative to control fibroblasts. A candidate list of 200 genes upregulated 2.8 -fold or more in pancreatic CAFs relative to control fibroblasts was sorted into representative biological function groups using the Partek Gene Ontology analysis. The high enrichment scores in the biological adhesion and developmental process groups indicate that the candidate gene list is enriched for genes involved in these processes. Supplementary Figure S2: Characterization of HPNE. Immunohistochemical staining reveals that HPNE cells express the mesenchymal marker, vimentin (a) and do not express the marker of activated fibroblasts, alpha-smooth muscle actin (b). HPNE cells lack expression of the cytokeratin 19 (c), an epithelial marker expressed in the pancreatic ductal epithelial cell line HPDE (d). Magnification: A: x20; B, C, D: x10. Supplementary Figure S3: Characterization of pancreatic CAFs. Cells within the CAF cultures have both a stellate and spindle-type morphology and lack expression of the epithelial cell marker cytokeratin 19 (a). They contain cytoplasmic lipid droplets (b) and express the mesenchymal cytoskeletal filament vimentin (c) as well as alpha-SMA (d), a marker of activated fibroblasts. Magnification: A, C, D: x10; B: x20. Figure is representative of all CAFs. Supplementary Figure S4: Immunohistochemical analysis of Smo expression in normal pancreatic tissue. Paraffin embedded sections were probed with an antibody against vimentin (a) or against Smo (b). Arrows indicate normal fibroblasts expressing vimentin but not Smo. Magnification: x20. 1 Supplementary Figure S5: Immunohistochemical analysis of Smo expression in whole tissue sections from pancreatic cancer tissue: Paraffin-embedded sections from primary pancreatic cancer tissue were probed with an antibody against alpha-SMA (a,c; low and high power images of the same section) to highlight the activated cancer associated fibroblasts. Consecutive sections were then probed with an antibody against Smo (b,d; low and high power images of the same section). Note that Smo expression is also detected in pancreatic cancer cells (b, d). Magnification: A, B: x10, C, D: x20. 2 Table 1. Genes Upregulated in Pancreatic CAFs Relative to Control Fibroblasts Gene symbolGene Assignment P value Fold Change BMPER NM_133468 // BMP binding endothelial regulator 0.0000 4.9 LOX NM_002317 // lysyl oxidase 0.0000 4.0 POSTN NM_006475 // periostin, osteoblast specific factor 0.0000 70.4 TNS1 NM_022648 // tensin 1 0.0000 4.8 KIAA1199 NM_018689 // KIAA1199 0.0000 35.1 OLFM1 NM_014279 // olfactomedin 1 0.0000 3.1 PKP2 NM_004572 // plakophilin 2 0.0000 11.6 MAPK13 NM_002754 // mitogen-activated protein kinase 13 0.0000 3.3 PTGFRN NM_020440 // prostaglandin F2 receptor negative regulator 0.0000 12.6 KRT19 NM_002276 // keratin 19 0.0000 3.5 KRT7 NM_005556 // keratin 7 0.0000 20.6 CCDC80 NM_199511 // coiled-coil domain containing 80 0.0000 3.3 ST6GALNAC5NM_030965 // ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1 0.0000 8.7 FZD7 NM_003507 // frizzled homolog 7 (Drosophila) 0.0000 3.3 NFIB NM_005596 // nuclear factor I/B 0.0000 9.9 ADAM12 NM_003474 // ADAM metallopeptidase domain 12 (meltrin alpha) 0.0000 24.3 KLHL13 NM_033495 // kelch-like 13 (Drosophila) 0.0000 15.2 TNIK NM_015028 // TRAF2 and NCK interacting kinase 0.0000 5.9 PTGIS NM_000961 // prostaglandin I2 (prostacyclin) synthase 0.0000 61.8 PTPRF NM_130440 // protein tyrosine phosphatase, receptor type, F 0.0000 2.8 KIAA0746 NM_015187 // KIAA0746 protein 0.0000 15.6 NKX2-3 NM_145285 // NK2 transcription factor related, locus 3 (Drosophila) 0.0000 3.5 VLDLR NM_003383 // very low density lipoprotein receptor 0.0000 7.3 CDKN1A NM_078467 // cyclin-dependent kinase inhibitor 1A 0.0000 2.9 LOC196264NM_198275 // hypothetical protein LOC196264 0.0000 3.4 C13orf33 NM_032849 // chromosome 13 open reading frame 33 0.0000 14.8 GATA6 NM_005257 // GATA binding protein 6 0.0000 4.8 NRXN3 NM_138970 // neurexin 3 0.0000 2.8 SYNC1 NM_030786 // syncoilin, intermediate filament 1 0.0000 5.5 HAPLN3 NM_178232 // hyaluronan and proteoglycan link protein 3 0.0000 3.8 DACT1 NM_016651 // dapper, antagonist of beta-catenin, homolog 1 0.0000 8.1 OSAP NM_032623 // ovary-specific acidic protein 0.0000 4.0 HAS2 NM_005328 // hyaluronan synthase 2 0.0000 5.1 FAM110B NM_147189 // family with sequence similarity 110, member B 0.0000 7.4 CREBL1 NM_004381 // cAMP responsive element binding protein-like 1 0.0000 3.1 LRRC2 NM_024750 // leucine rich repeat containing 2 0.0001 4.6 FST NM_013409 // follistatin 0.0001 8.8 DAPK1 NM_004938 // death-associated protein kinase 1 0.0001 5.4 TMEPAI NM_199170 // transmembrane, prostate androgen induced RNA 0.0001 5.9 SERPING1 NM_000062 // serpin peptidase inhibitor, clade G (C1 inhibitor) 0.0001 5.0 TSKU NM_015516 // tsukushin 0.0001 2.9 CDH2 NM_001792 // cadherin 2 0.0001 4.4 NDN NM_002487 // necdin homolog (mouse) 0.0001 5.4 C21orf56 BC084577 // chromosome 21 open reading frame 56 0.0001 2.8 GREM2 NM_022469 // gremlin 2, cysteine knot superfamily, homolog 0.0001 3.3 HSPB7 NM_014424 // heat shock 27kDa protein family, member 7 0.0001 5.2 ROR2 NM_004560 // receptor tyrosine kinase-like orphan receptor 2 0.0001 5.0 TNFAIP6 NM_007115 // tumor necrosis factor, alpha-induced protein 6 0.0001 9.6 LRIG1 NM_015541 // leucine-rich repeats and immunoglobulin-like domains 1 0.0002 3.1 BC036082 BC036082 // galectin-related protein 0.0002 3.5 DEPDC6 NM_022783 // DEP domain containing 6 0.0002 24.8 IL1A NM_000575 // interleukin 1, alpha 0.0002 5.6 SULF1 NM_015170 // sulfatase 1 0.0002 3.8 ADAM23 NM_003812 // ADAM metallopeptidase domain 23 0.0003 3.0 DPP4 NM_001935 // dipeptidyl-peptidase 4 0.0003 8.2 CDH13 NM_001257 // cadherin 13, H-cadherin (heart) 0.0003 4.2 SULF2 NM_198596 // sulfatase 2 0.0003 4.4 DOK5 NM_018431 // docking protein 5 0.0003 18.4 PTGS2 NM_000963 // prostaglandin-endoperoxide synthase 2 0.0003 7.2 LRRC32 NM_005512 // leucine rich repeat containing 32 0.0004 4.6 MYH10 NM_005964 // myosin, heavy chain 10, non-muscle 0.0004 6.1 ALDH1A3 NM_000693 // aldehyde dehydrogenase 1 family, member A3 0.0004 9.2 BST1 NM_004334 // bone marrow stromal cell antigen 1 0.0004 4.0 BC101260 BC101260 // ring finger protein 212 0.0004 4.0 MFAP5 NM_003480 // microfibrillar associated protein 5 0.0004 31.1 DIRAS1 NM_145173 // DIRAS family, GTP-binding RAS-like 1 0.0004 3.7 SLIT3 NM_003062 // slit homolog 3 (Drosophila) 0.0005 6.5 APOD NM_001647 // apolipoprotein D 0.0005 4.1 CDH11 NM_001797 // cadherin 11, type 2, OB-cadherin (osteoblast) 0.0006 12.5 SPOCK1 NM_004598 // sparc/osteonectin, cwcv and kazal-like domains 0.0006 16.4 ULBP1 NM_025218 // UL16 binding protein 1 0.0007 14.0 TSPYL5 NM_033512 // TSPY-like 5 0.0007 3.6 HOXC8 NM_022658 // homeobox C8 0.0007 4.1 FLJ11151 NM_018340 // hypothetical protein FLJ11151 0.0007 5.2 LRRC17 NM_001031692 // leucine rich repeat containing 17 0.0008 5.8 LAMC2 NM_005562 // laminin, gamma 2 0.0009 4.1 LOXL4 NM_032211 // lysyl oxidase-like 4 0.0010 3.7 SMO NM_005631 // smoothened homolog (Drosophila) 0.0010 2.9 MALL NM_005434 // mal, T-cell differentiation protein-like 0.0010 10.0 XYLT1 NM_022166 // xylosyltransferase I 0.0010 6.1 GDF15 NM_004864 // growth differentiation factor 15 0.0010 3.6 ISLR NM_201526 // immunoglobulin superfamily containing leucine-rich repeat 0.0011 26.6 KCTD15 NM_024076 // potassium channel tetramerisation domain containing 15 0.0011 3.0 GJA1 NM_000165 // gap junction protein, alpha 1 0.0012 4.5 IER3 NM_003897 // immediate early response 3 0.0013 4.2 C6orf85 NM_021945 // chromosome 6 open reading frame 85 0.0013 3.9 LOC387758NM_203371 // similar to RIKEN cDNA 0.0016 13.2 RHOJ NM_020663 // ras homolog gene family, member J 0.0017 13.3 HSD17B14 NM_016246 // hydroxysteroid (17-beta) dehydrogenase 14 0.0019 3.6 PTX3 NM_002852 // pentraxin-related gene, rapidly induced by IL-1 beta 0.0020 6.1 FGF2 NM_002006 // fibroblast growth factor 2 (basic) 0.0021 3.1 DPYSL3 NM_001387 // dihydropyrimidinase-like 3 0.0024 7.1 ID2 NM_002166 // inhibitor of DNA binding 2 0.0024 4.1 CNN1 NM_001299 // calponin 1, basic, smooth muscle 0.0024 3.8 CDCP1 NM_022842 // CUB domain containing protein 1 0.0028 4.4 THY1 NM_006288 // Thy-1 cell surface antigen1 0.0028 6.0 CGREF1 NM_006569 // cell growth regulator with EF-hand domain 1 0.0028 5.9 MATN2 NM_002380 // matrilin 2 0.0029 2.9 THBS2 NM_003247 // thrombospondin 2 0.0029 4.6 NGFB NM_002506 // nerve growth factor, beta polypeptide 0.0030 7.9 TINAGL1 NM_022164 // tubulointerstitial nephritis antigen-like 1 0.0031 4.4 USP53 NM_019050 // ubiquitin specific peptidase 53 0.0033 4.2 ANKRD37 NM_181726 // ankyrin repeat domain 37 0.0035 4.2 SH3PXD2B NM_001017995 // SH3 and PX domains 2B 0.0037 4.1 MGP NM_000900 // matrix Gla protein 0.0037 9.2 CD200 NM_001004196 // CD200 molecule 0.0039 5.3 NUAK1 NM_014840 // NUAK family, SNF1-like kinase, 1 0.0041 4.7 MBP NM_001025101 // myelin basic protein 0.0041 8.2 NEK7 NM_133494 // NIMA (never in mitosis gene a)-related kinase 0.0041 3.4 SNX25 NM_031953 // sorting nexin 25 0.0043 5.4 TNFRSF11BNM_002546 // tumor necrosis factor receptor superfamily, member 11b 0.0045 11.7 MEST NM_002402 // mesoderm specific transcript homolog (mouse) 0.0047 4.6 LOC554202AK124391 // hypothetical LOC554202 0.0049 2.8 CUGBP2 NM_006561 // CUG triplet repeat, RNA binding protein 2 0.0051 3.1 C10orf72 NM_001031746 // chromosome 10 open reading frame 72 0.0051 3.6 VCAN NM_004385 // versican 0.0052 3.6 FANK1 NM_145235 // fibronectin type III
Recommended publications
  • 1 1 Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human 1 Lung Adenocarcinoma 2 3 Hye Won Lee*1,2,3

    1 1 Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human 1 Lung Adenocarcinoma 2 3 Hye Won Lee*1,2,3

    Author Manuscript Published OnlineFirst on August 30, 2013; DOI: 10.1158/1078-0432.CCR-13-1181 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 1 Alpha-smooth muscle actin (ACTA2) is required for metastatic potential of human 2 lung adenocarcinoma 3 4 Hye Won Lee*1,2,3, Young Mi Park*3,4, Se Jeong Lee1,4,5, Hyun Jung Cho1,2, Duk-Hwan Kim6,7, 5 Jung-Il Lee2, Myung-Soo Kang3, Ho Jun Seol2, Young Mog Shim8, Do-Hyun Nam1,2,3, Hyeon 6 Ho Kim3,4, Kyeung Min Joo1,3,4,5 7 8 Authors’ Affiliations: 9 1Cancer Stem Cell Research Center, 2Department of Neurosurgery, 3Department of Health 10 Sciences and Technology, Samsung Advanced Institute for Health Sciences and 11 Technology (SAIHST), 4Samsung Biomedical Research Institute, 5Department of Anatomy 12 and Cell Biology, 6Department of Molecular Cell Biology, 7Center for Genome Research, 13 8Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University 14 School of Medicine, Seoul, Korea 15 16 *These authors contributed equally to this work. 17 18 Running title: ACTA2 confers metastatic potential on lung adenocarcinoma 19 Keywords: Non-small cell lung adenocarcinoma, alpha-smooth muscle actin, migration, 20 invasion, metastasis 1 Downloaded from clincancerres.aacrjournals.org on September 26, 2021. © 2013 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 30, 2013; DOI: 10.1158/1078-0432.CCR-13-1181 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 1 Financial support: This study was supported by a grant from the Korea Healthcare 2 Technology R&D Project, Ministry for Health & Welfare Affairs, Republic of Korea (A092255), 3 and the Basic Science Research Program, National Research Foundation of Korea by the 4 Ministry of Education, Science, and Technology (2011-009329 to H.
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)

    Viewed Under 23 (B) Or 203 (C) fi M M Male Cko Mice, and Largely Unaffected Magni Cation; Scale Bars, 500 M (B) and 50 M (C)

    BRIEF COMMUNICATION www.jasn.org Renal Fanconi Syndrome and Hypophosphatemic Rickets in the Absence of Xenotropic and Polytropic Retroviral Receptor in the Nephron Camille Ansermet,* Matthias B. Moor,* Gabriel Centeno,* Muriel Auberson,* † † ‡ Dorothy Zhang Hu, Roland Baron, Svetlana Nikolaeva,* Barbara Haenzi,* | Natalya Katanaeva,* Ivan Gautschi,* Vladimir Katanaev,*§ Samuel Rotman, Robert Koesters,¶ †† Laurent Schild,* Sylvain Pradervand,** Olivier Bonny,* and Dmitri Firsov* BRIEF COMMUNICATION *Department of Pharmacology and Toxicology and **Genomic Technologies Facility, University of Lausanne, Lausanne, Switzerland; †Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts; ‡Institute of Evolutionary Physiology and Biochemistry, St. Petersburg, Russia; §School of Biomedicine, Far Eastern Federal University, Vladivostok, Russia; |Services of Pathology and ††Nephrology, Department of Medicine, University Hospital of Lausanne, Lausanne, Switzerland; and ¶Université Pierre et Marie Curie, Paris, France ABSTRACT Tight control of extracellular and intracellular inorganic phosphate (Pi) levels is crit- leaves.4 Most recently, Legati et al. have ical to most biochemical and physiologic processes. Urinary Pi is freely filtered at the shown an association between genetic kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical polymorphisms in Xpr1 and primary fa- sodium-dependent phosphate transporters, NaPi-IIa/NaPi-IIc/Pit2. However, the milial brain calcification disorder.5 How- molecular identity of the protein(s) participating in the basolateral Pi efflux remains ever, the role of XPR1 in the maintenance unknown. Evidence has suggested that xenotropic and polytropic retroviral recep- of Pi homeostasis remains unknown. Here, tor 1 (XPR1) might be involved in this process. Here, we show that conditional in- we addressed this issue in mice deficient for activation of Xpr1 in the renal tubule in mice resulted in impaired renal Pi Xpr1 in the nephron.
  • Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene

    Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene

    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2006 Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene Yutao Liu University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Liu, Yutao, "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino- like Mouse Models: Tracking the Role of the Hairless Gene. " PhD diss., University of Tennessee, 2006. https://trace.tennessee.edu/utk_graddiss/1824 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Yutao Liu entitled "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences. Brynn H. Voy, Major Professor We have read this dissertation and recommend its acceptance: Naima Moustaid-Moussa, Yisong Wang, Rogert Hettich Accepted for the Council: Carolyn R.
  • Table 2. Significant

    Table 2. Significant

    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
  • Human Periprostatic Adipose Tissue: Secretome from Patients With

    Human Periprostatic Adipose Tissue: Secretome from Patients With

    CANCER GENOMICS & PROTEOMICS 16 : 29-58 (2019) doi:10.21873/cgp.20110 Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia PAULA ALEJANDRA SACCA 1, OSVALDO NÉSTOR MAZZA 2, CARLOS SCORTICATI 2, GONZALO VITAGLIANO 3, GABRIEL CASAS 4 and JUAN CARLOS CALVO 1,5 1Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina; 2Department of Urology, School of Medicine, University of Buenos Aires, Clínical Hospital “José de San Martín”, Buenos Aires, Argentina; 3Department of Urology, Deutsches Hospital, Buenos Aires, Argentina; 4Department of Pathology, Deutsches Hospital, Buenos Aires, Argentina; 5Department of Biological Chemistry, School of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires, Argentina Abstract. Background/Aim: Periprostatic adipose tissue Prostate cancer (PCa) is the second most common cancer in (PPAT) directs tumour behaviour. Microenvironment secretome men worldwide. While most men have indolent disease, provides information related to its biology. This study was which can be treated properly, the problem consists in performed to identify secreted proteins by PPAT, from both reliably distinguishing between indolent and aggressive prostate cancer and benign prostate hyperplasia (BPH) disease. Evidence shows that the microenvironment affects patients. Patients and Methods: Liquid chromatography-mass tumour behavior. spectrometry-based proteomic analysis was performed in Adipose tissue microenvironment is now known to direct PPAT-conditioned media (CM) from patients with prostate tumour growth, invasion and metastases (1, 2). Adipose cancer (CMs-T) (stage T3: CM-T3, stage T2: CM-T2) or tissue is adjacent to the prostate gland and the site of benign disease (CM-BPH). Results: The highest number and invasion of PCa.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2

    Supplementary Table 3 Complete List of RNA-Sequencing Analysis of Gene Expression Changed by ≥ Tenfold Between Xenograft and Cells Cultured in 10%O2

    Supplementary Table 3 Complete list of RNA-Sequencing analysis of gene expression changed by ≥ tenfold between xenograft and cells cultured in 10%O2 Expr Log2 Ratio Symbol Entrez Gene Name (culture/xenograft) -7.182 PGM5 phosphoglucomutase 5 -6.883 GPBAR1 G protein-coupled bile acid receptor 1 -6.683 CPVL carboxypeptidase, vitellogenic like -6.398 MTMR9LP myotubularin related protein 9-like, pseudogene -6.131 SCN7A sodium voltage-gated channel alpha subunit 7 -6.115 POPDC2 popeye domain containing 2 -6.014 LGI1 leucine rich glioma inactivated 1 -5.86 SCN1A sodium voltage-gated channel alpha subunit 1 -5.713 C6 complement C6 -5.365 ANGPTL1 angiopoietin like 1 -5.327 TNN tenascin N -5.228 DHRS2 dehydrogenase/reductase 2 leucine rich repeat and fibronectin type III domain -5.115 LRFN2 containing 2 -5.076 FOXO6 forkhead box O6 -5.035 ETNPPL ethanolamine-phosphate phospho-lyase -4.993 MYO15A myosin XVA -4.972 IGF1 insulin like growth factor 1 -4.956 DLG2 discs large MAGUK scaffold protein 2 -4.86 SCML4 sex comb on midleg like 4 (Drosophila) Src homology 2 domain containing transforming -4.816 SHD protein D -4.764 PLP1 proteolipid protein 1 -4.764 TSPAN32 tetraspanin 32 -4.713 N4BP3 NEDD4 binding protein 3 -4.705 MYOC myocilin -4.646 CLEC3B C-type lectin domain family 3 member B -4.646 C7 complement C7 -4.62 TGM2 transglutaminase 2 -4.562 COL9A1 collagen type IX alpha 1 chain -4.55 SOSTDC1 sclerostin domain containing 1 -4.55 OGN osteoglycin -4.505 DAPL1 death associated protein like 1 -4.491 C10orf105 chromosome 10 open reading frame 105 -4.491
  • Circular RNA Hsa Circ 0005114‑Mir‑142‑3P/Mir‑590‑5P‑ Adenomatous

    Circular RNA Hsa Circ 0005114‑Mir‑142‑3P/Mir‑590‑5P‑ Adenomatous

    ONCOLOGY LETTERS 21: 58, 2021 Circular RNA hsa_circ_0005114‑miR‑142‑3p/miR‑590‑5p‑ adenomatous polyposis coli protein axis as a potential target for treatment of glioma BO WEI1*, LE WANG2* and JINGWEI ZHAO1 1Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033; 2Department of Ophthalmology, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China Received September 12, 2019; Accepted October 22, 2020 DOI: 10.3892/ol.2020.12320 Abstract. Glioma is the most common type of brain tumor APC expression with a good overall survival rate. UALCAN and is associated with a high mortality rate. Despite recent analysis using TCGA data of glioblastoma multiforme and the advances in treatment options, the overall prognosis in patients GSE25632 and GSE103229 microarray datasets showed that with glioma remains poor. Studies have suggested that circular hsa‑miR‑142‑3p/hsa‑miR‑590‑5p was upregulated and APC (circ)RNAs serve important roles in the development and was downregulated. Thus, hsa‑miR‑142‑3p/hsa‑miR‑590‑5p‑ progression of glioma and may have potential as therapeutic APC‑related circ/ceRNA axes may be important in glioma, targets. However, the expression profiles of circRNAs and their and hsa_circ_0005114 interacted with both of these miRNAs. functions in glioma have rarely been studied. The present study Functional analysis showed that hsa_circ_0005114 was aimed to screen differentially expressed circRNAs (DECs) involved in insulin secretion, while APC was associated with between glioma and normal brain tissues using sequencing the Wnt signaling pathway. In conclusion, hsa_circ_0005114‑ data collected from the Gene Expression Omnibus database miR‑142‑3p/miR‑590‑5p‑APC ceRNA axes may be potential (GSE86202 and GSE92322 datasets) and explain their mecha‑ targets for the treatment of glioma.
  • Biological Pathways and in Vivo Antitumor Activity Induced by Atiprimod in Myeloma

    Biological Pathways and in Vivo Antitumor Activity Induced by Atiprimod in Myeloma

    Leukemia (2007) 21, 2519–2526 & 2007 Nature Publishing Group All rights reserved 0887-6924/07 $30.00 www.nature.com/leu ORIGINAL ARTICLE Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma P Neri1,2,3, P Tassone1,2,3, M Shammas1, H Yasui2, E Schipani4, RB Batchu1, S Blotta1,2,3, R Prabhala1, L Catley2, M Hamasaki2, T Hideshima2, D Chauhan2, GS Jacob5, D Picker5, S Venuta3, KC Anderson2 and NC Munshi1,2 1Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 2Boston VA Healthcare System, Department of Medicine, Harvard Medical School, MA, USA; 3Department of Experimental and Clinical Medicine, University of ‘Magna Græcia’ and Cancer Center, Catanzaro, Italy; 4Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA and 5Callisto Pharmaceuticals Inc., New York, NY, USA Atiprimod (Atip) is a novel oral agent with anti-inflammatory tion.7,8 Atip inhibits the inflammatory response and preserves properties. Although its in vitro activity and effects on signaling bone integrity in murine models of rheumatoid arthritis (RA),9–12 in multiple myeloma (MM) have been previously reported, here targets macrophages, inhibits phospholipase A and C in rat we investigated its molecular and in vivo effects in MM. Gene 13,14 expression analysis of MM cells identified downregulation of alveolar macrophages and exhibits antiproliferative and 15–17 genes involved in adhesion, cell-signaling, cell cycle and bone antiangiogenic activities in human cancer models. Impor- morphogenetic protein (BMP) pathways and upregulation of tantly, we have previously reported that Atip inhibits MM cell genes implicated in apoptosis and bone development, follow- growth, induces caspase-mediated apoptosis, blocks the phos- ing Atip treatment.
  • Development of an Enzyme-Linked Immunosorbent Assay for Detection of CDCP1 Shed from the Cell Surface and Present in Colorectal Cancer Serum Specimens

    Development of an Enzyme-Linked Immunosorbent Assay for Detection of CDCP1 Shed from the Cell Surface and Present in Colorectal Cancer Serum Specimens

    Accepted Manuscript Title: Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens Authors: Yang Chen, Brittney S. Harrington, Kevin C.N. Lau, Lez J. Burke, Yaowu He, Mary Iconomou, James S. Palmer, Brian Meade, John W. Lumley, John D. Hooper PII: S0731-7085(16)31477-7 DOI: http://dx.doi.org/doi:10.1016/j.jpba.2017.02.047 Reference: PBA 11114 To appear in: Journal of Pharmaceutical and Biomedical Analysis Received date: 23-12-2016 Revised date: 23-2-2017 Accepted date: 26-2-2017 Please cite this article as: Yang Chen, Brittney S.Harrington, Kevin C.N.Lau, Lez J.Burke, Yaowu He, Mary Iconomou, James S.Palmer, Brian Meade, John W.Lumley, John D.Hooper, Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens, Journal of Pharmaceutical and Biomedical Analysis http://dx.doi.org/10.1016/j.jpba.2017.02.047 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Development of an enzyme-linked immunosorbent assay for detection of CDCP1 shed from the cell surface and present in colorectal cancer serum specimens Yang Chena, Brittney S.
  • Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,